Cyclo Therapeutics, Inc.

NASDAQ:CYTH

0.68 (USD) • At close January 14, 2025
Bedrijfsnaam Cyclo Therapeutics, Inc.
Symbool CYTH
Munteenheid USD
Prijs 0.68
Beurswaarde 19,457,792
Dividendpercentage 0%
52-weken bereik 0.55 - 2.12
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. N. Scott Fine
Website https://www.cyclotherapeutics.com

An error occurred while fetching data.

Over Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment

Vergelijkbare Aandelen

InspireMD, Inc. logo

InspireMD, Inc.

NSPR

2.67 USD

Forte Biosciences, Inc. logo

Forte Biosciences, Inc.

FBRX

14.62 USD

Inspira Technologies Oxy B.H.N. Ltd. logo

Inspira Technologies Oxy B.H.N. Ltd.

IINN

1.03 USD

Nephros, Inc. logo

Nephros, Inc.

NEPH

1.5 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)